Skip to content

medcelerator · clinician one-pager

Weekly Shot When Too Many Red Blood Cells Need Frequent Draws

Mimrylo (rusfertide) for erythrocytosis in adults with polycythemia vera (PV)

FDA Approved · United States, Canada · September 4, 2026

Condition: Polycythemia Vera

Who this is for

The FDA labelled a once-weekly subcutaneous hepcidin mimetic for adults with polycythemia vera who still need frequent phlebotomies despite standard care. Health Canada NOC was not retrieved. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed. In Canada, authorisation is not confirmed; see Possible routes below if any are listed.

Ways to access this treatment

Possible routes (not confirmed)

General resources for further research

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/mimrylo-rusfertide